NuCyRNA Therapeutics aims to transform RNA-targeting therapeutics by co-targeting nuclear and cytoplasmic RNAs, starting in neurodegenerative diseases.

Aperture Therapeutics is developing a new class of medicines mimicking protective gene variants found in resilient individuals to treat neurodegeneration. Their lead drug candidates are oligonucleotides aimed that reversing chronic neuroinflammation in ALS and FTD. The team is also building an in vitro platform to evaluate the impact of diverse human genetics on drug efficacy.

Deck Bio is developing optimal multi-specific biologics for driving durable efficacy and safety in solid tumors using its proprietary drug discovery platform.

Rho Bio is developing therapies to restore lymphatic function. Built on discoveries from Yale and WashU, the team includes leading experts in lymphatic biology with an initial focus is on treating neuro-ophthalmic diseases caused by fluid and pressure buildup.

Verto is developing small molecule translation inhibitors for oncology, advancing programs against Myc and other hard-to-drug targets.

Velocity Bio is a Stanford University spin out accelerating allosteric drug discovery with microfluidics for difficult-to-drug enzyme targets.

Babylon Biosciences is a small molecule therapeutics company focused on diseases of the nervous system. The company closed an oversubscribed seed round by top tier investors in Q324 and is currently in stealth.

Developing a first in class suite of engineered tRNA therapeutics for oncology, Cloverleaf is a Yale spinout aiming to inhibit tRNA modifying enzymes that are overexpressed in cancer.

Umlaut is an EMBL spinout creating cancer and autoimmune therapeutics trough small molecule inhibition of tRNA modifications that globally dysregulate signaling pathway gene expression.